Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotech company developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Dr. Taylor Schreiber, Shattuck's CEO, will engage in a fireside chat with BTIG analyst Kaveri Pohlman on August 5 at 2:00 p.m. ET. The company will also be available for one-on-one meetings during the conference. A live webcast of the fireside chat will be accessible to conference participants.
Shattuck Labs (NASDAQ: STTK), un'azienda biotech in fase clinica che sviluppa proteine fusionali bifunzionali per il trattamento del cancro e delle malattie autoimmuni, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale sulla Biotecnologia BTIG. L'evento si terrà il 5 e 6 agosto 2024. Il Dr. Taylor Schreiber, CEO di Shattuck, parteciperà a una chiacchierata informale con l'analista BTIG Kaveri Pohlman il 5 agosto alle 14:00 ET. L'azienda sarà anche disponibile per incontri individuali durante la conferenza. Verrà trasmessa in diretta una webchat della chiacchierata informale, accessibile ai partecipanti della conferenza.
Shattuck Labs (NASDAQ: STTK), una empresa biotecnológica en etapa clínica que desarrolla proteínas de fusión bifuncionales para el tratamiento del cáncer y enfermedades autoinmunitarias, anunció su participación en la próxima Conferencia Virtual de Biotecnología BTIG. El evento está programado para el 5 y 6 de agosto de 2024. El Dr. Taylor Schreiber, CEO de Shattuck, participará en una charla informal con el analista de BTIG Kaveri Pohlman el 5 de agosto a las 2:00 p.m. ET. La empresa también estará disponible para reuniones individuales durante la conferencia. Se transmitirá una web en vivo de la charla informal, accesible para los participantes de la conferencia.
샤타크 랩스 (NASDAQ: STTK), 암 및 자가면역 질환 치료를 위한 이중 기능 융합 단백질을 개발하는 임상 단계의 생명공학 회사가 오는 BTIG 가상 생명공학 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 8월 5일부터 6일까지 예정되어 있습니다. 테일러 슈라이버 박사가 회사의 CEO로서 8월 5일 오후 2시(동부 표준시) BTIG 분석가인 카베리 포흘만과의 편안한 대화에 참여할 예정입니다. 회사는 또한 콘퍼런스 기간 동안 일대일 미팅을 진행할 예정입니다. 대화 내용의 실시간 웹캐스트는 콘퍼런스 참가자들이 접근할 수 있습니다.
Shattuck Labs (NASDAQ: STTK), une entreprise biotechnologique en phase clinique développant des protéines de fusion bifonctionnelles pour le traitement du cancer et des maladies auto-immunes, a annoncé sa participation à la prochaine Conférence Virtuelle sur la Biotechnologie BTIG. L'événement est prévu pour les 5 et 6 août 2024. Dr. Taylor Schreiber, PDG de Shattuck, participera à une discussion informelle avec l'analyste de BTIG Kaveri Pohlman le 5 août à 14h00 ET. L'entreprise sera également disponible pour des réunions individuelles pendant la conférence. Un webinaire en direct de la discussion sera accessible aux participants de la conférence.
Shattuck Labs (NASDAQ: STTK), ein biopharmazeutisches Unternehmen in klinischer Entwicklungsphase, das bifunktionale Fusionsproteine zur Behandlung von Krebs und Autoimmunerkrankungen entwickelt, gab seine Teilnahme an der bevorstehenden BTIG Virtuellen Biotechnologiekonferenz bekannt. Die Veranstaltung ist für den 5. und 6. August 2024 geplant. Dr. Taylor Schreiber, CEO von Shattuck, wird am 5. August um 14:00 Uhr ET in einem informellen Gespräch mit dem BTIG-Analysten Kaveri Pohlman teilnehmen. Das Unternehmen wird auch für Einzelgespräche während der Konferenz zur Verfügung stehen. Ein Live-Webcast des informellen Gesprächs wird für die Teilnehmer der Konferenz zugänglich sein.
- None.
- None.
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-one meetings at BTIG’s Virtual Biotechnology Conference, taking place August 5-6, 2024.
Presentation Details
Conference: BTIG Virtual Biotechnology Conference
Format: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: August 5, 2024
Time: 2:00 p.m. ET
A live webcast of the fireside chat will be available to conference participants. If you are interested in meeting with the Shattuck team during the conference, please reach out to your BTIG representative.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary ARC® platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) participating in the BTIG Virtual Biotechnology Conference?
Who will represent Shattuck Labs (STTK) at the BTIG Virtual Biotechnology Conference?
What type of products is Shattuck Labs (STTK) developing?
Will there be a webcast of Shattuck Labs' (STTK) presentation at the BTIG conference?
